key: cord-0960658-xmumursv
authors: Hernández Cordero, Ana I.; Li, Xuan; Yang, Chen Xi; Milne, Stephen; Bossé, Yohan; Joubert, Philippe; Timens, Wim; van den Berge, Maarten; Nickle, David; Hao, Ke; Sin, Don D.
title: Gene expression network analysis provides potential targets against SARS-CoV-2
date: 2020-12-14
journal: Sci Rep
DOI: 10.1038/s41598-020-78818-w
sha: 8ce90281781ea039f00775e91cb788a0ee552de0
doc_id: 960658
cord_uid: xmumursv

Cell entry of SARS-CoV-2, the novel coronavirus causing COVID-19, is facilitated by host cell angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). We aimed to identify and characterize genes that are co-expressed with ACE2 and TMPRSS2, and to further explore their biological functions and potential as druggable targets. Using the gene expression profiles of 1,038 lung tissue samples, we performed a weighted gene correlation network analysis (WGCNA) to identify modules of co-expressed genes. We explored the biology of co-expressed genes using bioinformatics databases, and identified known drug-gene interactions. ACE2 was in a module of 681 co-expressed genes; 10 genes with moderate-high correlation with ACE2 (r > 0.3, FDR < 0.05) had known interactions with existing drug compounds. TMPRSS2 was in a module of 1,086 co-expressed genes; 31 of these genes were enriched in the gene ontology biologic process ‘receptor-mediated endocytosis’, and 52 TMPRSS2-correlated genes had known interactions with drug compounds. Dozens of genes are co-expressed with ACE2 and TMPRSS2, many of which have plausible links to COVID-19 pathophysiology. Many of the co-expressed genes are potentially targetable with existing drugs, which may accelerate the development of COVID-19 therapeutics.

The Lung eQTL Consortium cohort used in this gene network analysis is described in Table 1 . Supplementary  Fig. S1 shows the expression levels of ACE2 and TMPRSS2 in the three centres that are part of the Lung eQTL Consortium (see Methods); ACE2 had low to moderate expression levels in lung tissue; whereas TMPRSS2 was highly expressed. Based on the study cohort lung expression profile, we determined that ACE2 and TMPRSS2 were contained in distinct modules. The module containing ACE2 (ACE2 module) included 681 unique genes, while the modules containing TMPRSS2 (TMPRSS2 module) encompassed 1,086 unique genes. The hub gene for the ACE2 module was TMEM33, and hub gene for the TMPRSS2 module was PDZD2 (see Methods for the definition of 'hub gene'). Figure 1 shows the top 50 genes with the highest connectivity to ACE2 and TMPRSS2 within their respective modules, based on the WGCNA analysis. ACE2 module. We filtered out the genes with consensus module membership (MM) (see Methods) < 0.20, which left 578 genes for the subsequent analyses. The MM for ACE2 was 0.25. We utilized genes in the ACE2 module to execute a pathway enrichment analysis, which showed significant enrichment of two Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways ('Lysosome' , 'Metabolic pathways') (Supplementary Table S3 ) and five Gene Ontology (GO) biologic processes (FDR < 0.05) (Supplementary Table S4 ).

ACE2-correlated genes. The expression of 561 genes in the ACE2 module was significantly correlated with ACE2 levels (FDR < 0.05), and only three of those genes were negatively correlated with ACE2. Although a large proportion of genes were significantly related to ACE2 expression levels, only 78 genes had moderate or high correlations (r > 0.3).

The PCCB gene was most strongly correlated with ACE2 expression (r = 0.45, Supplementary Table S1). Of the top 10 genes most strongly correlated with ACE2, three genes (PCCB, PIGN and ADK) were part of the KEGG 'metabolic pathway' which showed enrichment with ACE2 module genes (Supplementary Table S3 ). Furthermore, out of the top 20 genes, only WDFY3 was found in 'process utilizing autophagic mechanism' GO process that was enriched with ACE2 module genes (Supplementary Table S4) .

We identified 78 genes that showed moderate correlation (r > 0.3) with ACE2 expression. Of these, 46 genes had biological and/or druggability information available (details are presented in Supplementary Table S1). We used these genes to construct a 'map' of biological information (Supplementary Fig. S2 ). Based on the druggability Table S2 ). Next, we identified 325 genes that were moderately or highly correlated with TMPRSS2 gene expression levels (r > 0.30), of these 67 were drug targets or were part of key pathways that could be targeted by drug compounds, including TMPRSS2 (see Methods), however we focused on those that are drug targets ( Table 3) . The genes are shown in Fig. 2 , grouped www.nature.com/scientificreports/ based on the availability of biological information. The A6 group contained the genes with the largest amount of biological information in the explored bioinformatics databases. Most genes in Fig. 2 had information on druggability scores, and mouse and human phenotypes (A3 group); details on the genes biological information are presented in the Supplementary Table S2 . We later explored the drug-gene interactions of the genes described in Fig. 2 ; 52 of these genes were found to interact with known drugs. The genes with the highest druggability score (Tier 1) are presented in Table 3 . Furthermore, Table 3 includes one of the genes (ADRB2) that is part of the GO biological process related to TMPRSS2 ('Receptor-mediated endocytosis').

We investigated the effects of risk factors for COVID-19 on the expression of the genes shown in Tables 2 and 3 . A full list of differential expressed genes (FDR < 0.05) with known drug-gene interactions is presented in Supplementary Table S7. Some illustrative examples are shown in Fig. 3 , including the effect of chronic obstructive pulmonary disease (COPD) on GART expression (Fig. 3a) , the effect of diabetes on LRRK2 expression (Fig. 3b) , and the effect of smoking on ADK, CD55, DPP4 and MET expression ( Fig. 3c-f ).

There is a scarcity of therapeutic treatments specific for this virus and for severe COVID-19 pneumonia. ACE2 and TMPRSS2 are key proteins involved in the cellular entry mechanism of SARS-CoV-2 to infect the lungs of the human host. Because one of the rate-limiting steps in this process is the overall availability of these proteins on the surface of lung epithelial cells 15 , careful evaluation of ACE2 and TMPRSS2 biology may enable identification Table 3 . Drug-gene interactions of TMPRSS2-correlated genes. ‡ from Drug-Gene Interaction Database (DGIdb) 13 . r(TMPRSS2): Pearson correlation coefficient between gene and TMPRSS2 expression (adjusted for sex, age and centre). p: significance of the Pearson correlation coefficient (corresponds to Fisher's Z score value), adjusted for false discovery rate (FDR). www.nature.com/scientificreports/ of possible therapeutic targets against SARS-CoV-2 infection. In this study, by using a network analysis of genome-wide gene expression in lung tissue, we were able to identify a set of genes that interact with ACE2 and TMPRSS2, and thus may be drug targets.

Other investigators have explored lung gene coexpression in order to identify potential drug targets in COVID-19 16 . Recently, Cava et al. reported genes that are co-expressed with ACE2 using a series of pairwise correlations, and assembled the correlated genes into a protein-protein interaction network. In this way, they Correlation level and annotation of TMPRSS2-correlated genes. Each bar represents a single gene (all with druggability scores Tier 1-3 12 ), and Pearson correlation coefficient (r) between the gene and TMPRSS2 within the module is shown on the y axis. Colours of bars represent combined biological information: aqua (group A0) represents those genes with only druggability information; orange (group A1) represents genes that are related to human diseases based Online Mendelian Inheritance in Man (OMIM) and ClinVar databases; purple (group A2) represents genes with phenotypic information on knockdown or knockout mouse models based on Mouse Genome Informatics (MGI) database; pink (group A3) represents genes with phenotypic information on knockdown or knockout mouse models based on MGI database, and that are related to human diseases based OMIM and ClinVar data bases; green (group A4) represents genes related to human diseases based OMIM and ClinVar databases and with genetic variants associated to lung function traits 14 ; yellow (group A5) represents genes with phenotypic information on knockdown or knockout mouse models based on MGI database, and with genetic variants associated to lung function traits 14 ; brown (group A6) represents genes with phenotypic information on knockdown or knockout mouse models based on MGI database, and that are related to human diseases based OMIM and ClinVar data bases, and with genetic variants associated to lung function traits 14 . Figure was created using R 3.6 (https ://www.r-proje ct.org/) 11 . Scientific Reports | (2020) 10:21863 | https://doi.org/10.1038/s41598-020-78818-w www.nature.com/scientificreports/ were able to identify 526 genes with significant (p < 0.01) correlation to ACE2 and 36 existing drugs known to interact with protein-coding, ACE2-related genes. While this approach was a useful exploration, we believe our approach has several advantages. First, WGCNA incorporates the coordinated expression of genes and thus is more reflective of the complex regulation of gene expression. Second, our analysis controls for the false discovery rate rather than setting a nominal p value cutoff that does not correct for multiple testing. Third, we also explored coexpression with the host cell protease gene TMPRSS2, which revealed many more targets with high druggability and known drug-gene interactions than those related to ACE2. Finally, we used gene expression data from a large lung tissue data set with detailed clinical phenotype information, which allowed us to relate our findings to known risk factors for severe COVID-19. Despite the differences in approach, our results show some overlap with those of Cava et al. 16 -12 ACE2-correlated genes were identified by both approaches, suggesting that these may be some of the more robust targets for further investigation. One notable gene that was confirmed by our study was ADK 16 . This gene is a key regulator of extracellular and intracellular adenine nucleotides 17, 18 . ADK inhibition attenuates lung injury in mice 19 , while in humans, cigarette exposure upregulates expression of ADK in lung tissue. We posit a role for ADK in COVID-19. We believe that up-regulation of ADK expression may increase the concentration of adenosine in the lungs, which in turn can enhance viral replication. Previous work has shown that silencing ADK decreased influenza replication in an in vitro model 20 . Another study showed that ADK can activate didanosine 21 , a dideoxynucleoside analogue of adenosine that inhibits retro-transcription and is used in the treatment of HIV. Although this drug was recently nominated for drug repurposing as a potential treatment against COVID-19 22 , the biology of this drug is complex, particularly given the detrimental effect of ADK on lung injury.

Another ACE2-correlated gene that emerged from this study was DPP4. DPP4 encodes the dipeptidyl-peptidase 4 (DPP-4) glycoprotein, which plays a major role in glucose and insulin metabolism and is linked to diabetes, now established as a key risk factor for severe COVID-19 including mortality 23 . DPP-4 is the functional receptor for the Middle East Respiratory Syndrome (MERS) coronavirus and interacts with dozens of drugs. DPP-4 inhibitors, which are used in the treatment of diabetes, appear to reduce macrophage infiltration and insulin resistance but have not been shown to increase the risk of infection in diabetic patients 24 . However, the effects of DPP-4 inhibitors on the immune response are not well understood. Because of the similarities between MERS and SARS-Cov-2, this is an interesting potential target, particularly for patients with diabetes. Thus, the DPP-4 pathway poses an intriguing possibility for novel COVID-19 therapeutics.

The HDAC8 gene is an exciting potential target because of its role in pulmonary fibrosis (PF) and its interaction with histone deacetylase (HDAC) inhibitors. HDAC inhibitors have shown promise against fibrotic www.nature.com/scientificreports/ diseases 25 . The overexpression of HDACs is suggested to contribute to the process of bronchiolization in patients with IPF 26 . Viral infection increases the risk of PF 27 and it is reported that HDAC8 inhibition ameliorates PF 28 ; moreover we found that cigarette exposure, a known risk factor for both COVID-19 and IPF, increases the expression of HDAC8 in lung tissue. Therefore, targeting the PF mechanisms through HDAC inhibitors pose an interesting therapy to further explore. Furthermore, the CD55 or complement decay-accelerating factor, an inhibitor of complement activation, is one of the few genes that was part of this process. The complement system has a major role in the immune response to viruses and triggers a proinflammatory cascade 29 . CD55, which is highly expressed in lung tissue, prevents the formation of C3 convertase 30 and therefore also inhibits the formation of C3 complement. C3-deficient mice show less respiratory dysfunction and lower levels of cytokines and chemokines in lungs in response to SARS-CoV 31 . Thus, it is possible that preventing the formation of C3 via CD55 could be beneficial in COVID-19. Fortunately, known compounds such as chloramphenicol already exist that specifically target CD55 29, 32 .

As noted above, we have identified a set of genes that interact with potential therapeutic targets, which could be explored as treatments against COVID-19. The main strength of our study is the large number of lung tissue specimens with detailed clinical phenotypic data. This allowed us to not only identify genes related to ACE2 and TMPRSS2 expression, but also to determine the effects of various clinical factors on the lung tissue expression of these genes. However, there were limitations to this study. First, we used an in-silico approach to identify ACE2 and TMPRSS2 correlated genes, but we did not confirm these association in vivo or determine how these correlated genes physically interacted with ACE2 and TMPRSS2. Second, we identified the most promising drugs based on drug-gene interactions from bioinformatic databases, but we did not validate their effects on gene and/ or protein expression through in vitro experiments. Third, the lungs of our study cohort were not exposed to SARS-CoV-2, therefore it is possible that the gene expression of these key identified genes in lung tissue could be changed upon SARS-CoV-2 infection. Lastly, the cohort used for gene expression was of European ancestry and the results may not be generalizable to other ethnic groups, which is of critical importance in a global pandemic.

In summary, ACE2 and TMPRSS2 gene networks contained genes that could contribute to the pathophysiology of COVID-19. These findings show that computational in silico approaches can lead to the rapid identification of potential drugs, which could be repurposed as treatments against COVID-19. Given the exponential spread of COVID-19 across the globe and the unprecedented rise in deaths, such rapidity is necessary in our ongoing fight against the pandemic. Gene expression network analysis. Using the WGCNA 8 R package, we explored gene networks correlated to ACE2 and TMPRSS2 in order to identify potential interactions in the Lung eQTL Consortium cohort. WGCNA clusters co-expressed genes into networks and creates "modules", which are defined as groups of highly interconnected genes. For this analysis we identified signed consensus modules among the three centres in our study cohort. Briefly, WGCNA generated a signed coexpression matrix based on the correlation between genes, which later was transformed into an adjacent matrix by raising the coexpression to a soft threshold power (β). For our study we used a β = 6 and a minimum module size of 100 probe sets. For each probe set in the modules a 'Module Membership' (MM) was calculated by correlating the gene's expression with the respective module's expression (eigengene), i.e. the first principal component of each module gene expression profile; the gene with the highest MM was termed the 'hub gene' . Note that the modules were determined at a gene probe level and some of the genes mapped to more than one probe; the slight overlap of genes between modules suggested heterogeneity between the gene probes, thus we did not consider these genes as relevant candidates in our study.

of KEGG pathways and GO biological processes was performed using the R package WebGestaltR (0.4.3) 33 . This analysis was applied to the genes (with MM > 0.20) in the modules containing ACE2 (ACE2 module) and TMPRSS2 (TMPRSS2 module). Significant enrichment was established at FDR < 0.05. For each gene in the ACE2 and TMPRSS2 modules with MM > 0.20, we determined the Pearson correlation between the expression level of the gene and that of ACE2 or TMPRSS2. First the expression was adjusted for age and sex by using a robust linear module, and the residuals were extracted (for each centre separately), we then used these to calculate the correlation coefficients for the three centres separately, and then combined them using correlation meta-analysis via the R package metafor 34 . Significant correlations were set at FDR < 0.05 and in the downstream analyses, we focused on genes that correlated to ACE2 or TMPRSS2 with r > 0.30.

We cross-referenced the ACE2 and TMPRSS2 correlated genes with the Mouse Genome Informatics (MGI), the Online Mendelian Inheritance in Man (OMIM), and the ClinVar databases in order to identify biologically relevant genes. We determined druggability scores according to methods of Finan et al. 12 . Tier 1 refers Scientific Reports | (2020) 10:21863 | https://doi.org/10.1038/s41598-020-78818-w www.nature.com/scientificreports/ to genes that are targets of small molecules and/or biotherapeutic drugs; Tier 2 score indicates gene encoding targets with a known bioactive drug-like small molecule binding partner and ≥ 50% identity (over ≥ 75% of the sequence) with an approved drug target; and Tier 3 denotes protein coding genes with similarities to drug targets and are members of key druggable gene families. We also interrogated the Drug-Gene Interaction database (DGIdb) 13 of the genes. DGIdb defines drug-gene interaction as a known interaction (i.e.: inhibition, activation) between a known drug compound and a target gene.

Differential expression of ACE2 and TMPRSS2 correlated genes. We investigated the effects of possible risk factors for COVID-19 severity (e.g. smoking, diabetes, asthma, COPD, cardiac disease, and hypertension) on the expression of druggable genes that were correlated with ACE2 or TMPRSS2. Then, the differential expression was assessed for each gene-risk factor pair by a robust linear regression using the package MASS 35 in R, in which the dependent variable was the gene expression and the explanatory variable was the risk factor. The differential expression analysis on smoking was adjusted for sex, age and centre, and the analyses on diabetes, COPD and cardiac disease and hypertension were adjusted for sex, age, smoking status and centre. We set statistically significant differential expression FDR < 0.05.

An interactive web-based dashboard to track COVID-19 in real time

Expression of SARS-CoV-2 entry receptors in the respiratory tract of healthy individuals, smokers and asthmatics

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

The type I interferon response in COVID-19: implications for treatment

Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2

WGCNA: an R package for weighted correlation network analysis

Lung eQTLs to help reveal the molecular underpinnings of asthma

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

R: A language and environment for statistical computing. R Foundation for Statistical Computing

The druggable genome and support for target identification and validation in drug development

DGIdb 2.0: mining clinically relevant drug-gene interactions

New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries

SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells

In silico discovery of candidate drugs against Covid-19

Adenosine kinase: exploitation for therapeutic gain

The equilibrative nucleoside transporter family, SLC29. Pflugers Arch

Inhibition of adenosine kinase attenuates acute lung injury

Identification of host kinase genes required for influenza virus replication and the regulatory role of MicroRNAs

Metabolic pathways for the activation of the antiretroviral agent 2' ,3'-dideoxyadenosine in human lymphoid cells

Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data. mSystems 5

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials

Histone deacetylase: a potential therapeutic target for fibrotic disorders

Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis

Viral infection increases the risk of idiopathic pulmonary fibrosis: a meta-analysis

HDAC8 inhibition ameliorates pulmonary fibrosis

Complement as a target in COVID-19?

Beyond the role of CD55 as a complement component

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis

COVID-19: immunopathology and its implications for therapy

WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs

Conducting Meta-Analyses in R with the metafor Package

The full results obtained in this analysis are provided in the Supplementary Tables associated to this manuscript. Lung eQTL study data used for this study can be obtained through GEO platform accession number GSE23546 and the dbGaP Study Accession phs001745.v1.p1.Received: 28 June 2020; Accepted: 30 November 2020

The eQTL data from Laval University were generated from tissues obtained through the Quebec Research Respiratory Network Biobank, IUCPQ site. We acknowledge Compute Canada and WestGrid, which provided computational resources to conduct this research.

Supplementary Information The online version contains supplementary material available at https ://doi. org/10.1038/s4159 8-020-78818 -w.Correspondence and requests for materials should be addressed to A.I.H.C.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.